



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 02-6-2008

Mr. Yasin Tahir,
Director General, IPO-Pakistan
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 03-5-2008 TO BE PUBLISHED 03-6-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 02-6-2008

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 03-5-2008 TO BE PUBLISHED 03-6-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

451/2008	<u>28-4-2008</u> F. L. Smith A/S. Denmark (Priority 12-6-07 Denmark)	“Method and plant for the simultaneous production of electricity and cement clinker”
452/2008	F. L. Smith A/S. Denmark (Priority 27-6-07 Denmark)	“Roller bearing”
453/2008	F. L. Smith A/S. Denmark (Priority 11-7-07 Denmark)	“Roller Mill”
454/2008	F. L. Smith A/S. Denmark (Priority 27-6-07 Denmark)	“Roller Mill”
455/2008	<u>29-4-2008</u> Bristol-Myers Squibb Company, USA (Priority 04-5-07 USA)	”[6, 5] and [6, 7]-bicyclic GPR119 G protein-coupled receptor agonists”
456/2008	Bristol-Myers Squibb Company, USA (Priority 04-5-07 USA)	”[6, 5] bicyclic GPR119 G protein-coupled receptor agonists”
457/2008	Telefonaktiebolaget LM Ericsson (publ), Sweden (Priority 03-5-07 USA)	“Early reflection method for enhanced externalization”
458/2008	Pfizer Limited, United Kingdom (Priority 01-5-07 USA)	“Combinations comprising pregablin”
459/2008	Pfizer Limited, United Kingdom (Priority 03-5-07 USA)	“Pyridine derivatives”

460/2008	ProMetic BioSciences Inc. (CA/CA) Canada (Priority 30-4-07 USA)	“Compounds, compositions containing such compounds, and methods of treatment of cancer and autoimmune diseases using such compounds”
461/2008	KDM Engineering GmbH Austria (Priority 22-5-07 Austria)	“Use of an additive for a building material and method for producing a building material”
462/1008	Imaspro Biotech Sdn Bhd. Malaysia (Priority 07-5-07 Malaysia)	“Oil in water pesticide formulation”
	<u>30-4-2008</u>	
463/2008	AstraZeneca AB, Sweden (Priority 04-5-07 USA)	“Chemical compounds”
464/2008	Masonite Corporation, USA (Priority 01-5-07 USA)	“Nestable molded articles, and related assemblies and methods”
465/2008	1. Muhammad Yasin Khan 2. Iftikhar Ahmed Multan, Pakistan	“Gravitational weight lessor perpetual gear system”
466/2008	GlaxoSmithKline Biologicals s.a. Belgium (Priority 02-5-07 GB)	“Vaccine”
467/2008	Nokia Corporation, Finland (Priority 30-4-07 USA)	“Method and apparatus for providing a data retransmission scheme”
	<u>02-5-2008</u>	
468/2008	Mr. Muhammad Saeed Karachi, Pakistan.	“LCD touch screen, LPG dispenser”
469/2008	Mr. Aamer Hussain Karachi, Pakistan	“LCD touch screen panel for CNG compressors”
470/2008	Amira Pharmaceuticals, Inc. USA (Priority 04-5-07 USA)	“5-lipoxygenase-activating protein (Flap) inhibitors”
471/2008	Nokia Corporation, Finland (Priority 02-5-07 USA)	“System and method for improving reordering functionality in radio communications”

<u>03-5-2008</u>		
472/2008	DSM IP Assets B.V., Netherlands, (Priority 04-5-07 EU)	“Composition comprising anti-bridging agent”
473/2008	1. Baxter International Inc., USA 2. Baxter HealthCare S.A., Switzerland (Priority 04-5-07 US)	“Formulation of sucrose solutions for continuous ultracentrifugation for virus purification”
474/2008	1. Baxter International Inc., USA 2. Baxter HealthCare S.A., Switzerland (Priority 04-5-07 US)	“Two step temperature profile for the propagation of viruses”
475/2008	BP Corporation North America Inc. USA (Priority 04-5-2007 USA)	“Process and catalyst for oxidizing aromatic compounds”
476/2008	Wyeth, USA (Priority 04-5-07 USA)	“Tricyclic compounds as matrix metalloproteinase inhibitors”
477/2008	Mitsubishi Tanabe Pharma Corporation, Japan (Priority 21-10-05 Japan) Divisional	“A pharmaceutically acceptable salt of a pyrazolo [1, 5-a] pyrimidine compound”



APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

- | | | | |
|----------|--------------------------------|--|--------|
| 365/1995 | Eli Lilly and Company.
USA. | “A physical form of (R) -7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-H][2,3]benzodiazepine” | |
| | | (C07D 243/38 , A61K 31/50 | 139526 |
| | | A physical form of (R) -7-acetyl-5-(4-aminophenyl)-8, 9-dihydro-8-methyl-7H-1, 3-dioxolo [4, 5-h] [2, 3] benzodiazepine having an X-ray powder diffraction pattern with d spacings at 10.61, 8.78, 5.83, 4.13 and 3.74 A. The compound is useful as an AMPA antagonist. | |
| 107/1998 | Glaxo Wellcom Inc.
USA | “Metered dose inhaler for fluticasone propionate” | |
| | | (A61M 15/02 | 139527 |
| | | A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one ore more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising fluticasone propionate or a physiologically acceptable solvate thereof and a fluorocarbon propellant optionally in combination with one or more other pharmacologically active agents or | |

1051/2004 Fumakilla Limited
Japan.

one or more excipients.

“A chemical cartridge and a blower type chemical diffusing apparatus comprising thereof”

(A01M 1/20

139528

A blower type chemical diffusing apparatus is disclosed that is small in thickness, simple in structure and reduced in cost structurally to allow the chemical and battery to be exchanged readily and to facilitate electrically connecting battery to the motor in the blower. The apparatus casing comprises a first and a second side casing counterpart hinged together to allow its opening and closure, a blower with a motor and fan mounted in the first casing body, a chemical cartridge disposed between the blower and the second casing body and containing a chemical impregnated body that comprises a carrier in the form of a sheet impregnated with chemical. Also provided in the first casing body is a battery accommodating recess in which dry cells may removably be accepted to drive the motor and thereby to rotate the fan. Air is thus forced to flow through the chemical cartridge.

A chemical cartridge is also provided that is thinned, capable of sustaining its given shape, free from contaminating the hand and not wasting chemical. It uses a chemical impregnated body in the form of an air permeable and liquid absorptive sheet impregnated with chemical, which is loaded in a receptacle having a base and a cover member adapted to hold the sheet body between them. The retainer receptacle has a central, a peripheral and intermediate support sections formed to provide recesses between them and spaced between them and the lower face of the chemical impregnated body while the cover member has a central, peripheral and intermediate hold sections formed with airflow holes to allow air to flow into those spaces, there by permitting those portions of impregnated chemical which are present between the hold and support sections to be entrained in air passing through the spaces and emanating into the atmosphere.

A chemical impregnated body having a honeycomb structure is also provided to ease the user to refill the cartridge used out. An air permeable and liquid

absorptive sheet body is disposed adjacent to a honeycomb body and in intimate contact with one of its open side faces and the bodies are impregnated with chemical. When the cartridge is depleted of its chemical, liquid chemical is supplied into the sheet body and allowed to permeate it over its entire area and then the honeycomb body over its entire area.

36/2005 Honda Motor Co., Ltd.
Japan.

“Valve operation device for internal combustion engine”

(F01L 1/04)

139529

A valve characteristic varying mechanism M of a valve operation device 40 changes an overlap period and a non-overlap period to thereby control an internal EGR rate. The valve characteristic varying mechanism M comprises a control mechanism M3 for swinging an intake link mechanism connected to an intake cam 53 and an exhaust link mechanism connected to an exhaust cam 54 about a camshaft 50, and a driving mechanism for driving the control mechanism M3. The control mechanism M3 connects the driving mechanism with the respective link mechanisms so that a retarded amount in an opening time of an intake valve 22 by the intake link mechanism is greater than an advanced amount of a closing time of an exhaust valve 23 by the exhaust link mechanism when assuming the same driving amount by the driving mechanism in a direction where the internal EGR rate increases.


65/2005 Pfizer Products Inc.
USA

“Substituted quinoline compound”

(C07D 215/06)

139530

This invention relates to MTP/Apo-B secretion inhibitors of Formula (I)



Wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compound, and methods of use of the compound and composition. The compound of the invention are useful in treating obesity and associated diseases, conditions or disorders.

254/2005 Chiesi Farmaceutici
SPA.
Italy.

“pharmaceutical composition for dry powder inhaler comprising a low-dosage strength active ingredient”

(A6IK 9/14)

139531

The invention provides a formulation to be administered as dry powder for inhalation suitable for efficacious delivery of low-dosage strength active ingredients to the low respiratory tract of patients. In particular, the invention provides a formulation comprising microparticles constituted of particles of a low-dosage strength active ingredient and particles of an excipients wherein the MMD of the microparticles is comprised between 2 and 15 micron, at least 10% of the microparticles has a mass diameter (MD) higher than 0:5 and 1:100, and the process of preparation thereof.


260/2005 Pfizer Products Inc.
USA

“Imidazole compound”

(C07D 233/54)

139532

The present invention relates to compound of the Formula I



Wherein R¹, R², R³, R⁴, R⁶, R⁷, and A are as defined. Compound of the formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative

338/2005	Honda Motor Co., Ltd. Japan.	<p>and/or neurological disorders, e.g., alzheimer's disease, in a mammal comprising compound of the formula I.</p> <p>“Intake apparatus for vehicle”</p> <p>(F02M 35/10, F02M 35/16)</p>	139533
		<p>An intake apparatus for a vehicle is provided which can cover the outer periphery of an intake duct over a wide range to enhance the waterproof performance and keep the gap between a rear fender and an air cleaner case to enhance the drainage performance. In the intake apparatus for a vehicle, an intake duct 53 for taking air into an air cleaner case 51 is provided for the air clear case 51 adjacent a case cover 61 and a duct cover 112 for covering an outer circumference of the intake duct 53 is integrally provided on the case cover 61.</p>	
68/2006	Janssen Pharmaceutica N.V. Belgium.	<p>“Tetrahydro-furan-2-carboxylic acid-[3-(2,3,5,6-tetrahydro-imidazo [2.1-b]thiazole-6-yl)-phenyl]-amide”</p> <p>(C07D 513/04)</p>	139534
		<p>The present invention relates to the novel anthelmintic compound tetrahydro-furan-2-carboxylic acid-[3-(2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole-6-yl)-phenyl]-amide and the stereochemically isomeric form thereof, as well as pharmaceutical composition comprising said novel compound, process for preparing said compound and composition, and the use thereof as a medicine, in particular in treatment, control and prevention of endo-and ectoparasite infections in warm-blooded animals.</p>	
418/2006	Boehringer Ingelheim International GmbH. Germany.	<p>“A crystalline form of 1-chloro-4-(B-D-glucopyranos-1-yl)-2-[4-(S)-tetrahydrofuran-3-yloxy]-benzyl]-benzene, method of its preparation”</p> <p>(C07D 309/10 , A61K 31/351)</p>	139535
		<p>The invention relates to a crystalline form of 1-</p>	

chloro-4-(β-D-glucopyranos-1-yl)-2-[4-(S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to

the use thereof for preparing medicaments. The crystalline form preferably has an x-ray powder diffraction pattern that comprises peaks at 18.84, 20.36 and 25.21 degrees 2θ (±0.05 degrees 2θ), wherein said X-ray powder diffraction pattern is made using CuKα1 radiation. The crystalline form can be used for preparing a pharmaceutical composition which is suitable for the treatment or prevention of diseases or conditions which can be influenced by inhibiting the sodium-dependent glucose cotransporter SGLT. In particular the crystalline form is useful in the treatment of diabetes mellitus. The crystalline form can be obtained by a method comprising the following steps:

- (a) dissolving 1-chloro-3-(β-D-glucopyranos-1-yl)[4-(S)-tetrahydrofuran-3-yloxy)benzyl]benzene in a solvent or a mixture of solvents to form a saturated or nearly saturated solution;
- b) storing the solution to precipitate the crystalline form out of solution and thus to yield a suspension;
- c) isolating the precipitate from the suspension; and
- d) drying the precipitate until any excess of said solvent or mixture of solvents has been removed.

1388/2006 Reckitt Benckiser (UK) Limited.
United Kingdom.

“A spraying device for spraying fragrance”

(B65D 83/16)

139536

A spraying device for spraying fragrance, pest control composition and/or a sanitizing composition held within a pressurized container, the spraying device comprising a container receiving section (13) and a switching section (10) wherein the switching section (10) incorporates a solenoid switch.

1389/2006 Reckitt Benckiser (UK) Limited.

“A spraying device for spraying fragrance”

(B65D 83/16)

139537

A spraying device for spraying fragrance, pest control composition and/or a sanitizing composition held within a pressurized container, the spraying device comprising a container receiving section (13) and a switching section (10) wherein the switching section (10) incorporates a solenoid switch.


421/2007 Pfizer Products Inc.
USA

“Pharmaceutically acceptable salt of imidazole compound”

(C07D 233/54)

139538

The present invention relates to compound of the Formula



Wherein R¹, R², R³, R⁴, R⁶, R⁷ and A are as defined. Compound of the formula I have activity inhibiting production of AB-peptide. The invention also relates to pharmaceutical composition and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., alzheimer's disease, in a mammal comprising compound of the formula I.

96969696969696969696969696969696

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139303	British Biotech Pharmaceuticals Limited United Kingdom	218/1999
139304	Warner-Lambert Company, USA	869/2002
139305	Pharmaceutica Italia S.p.A. Italy	797/2003

(Mrs. Yasmeen Abbasi)
Controller of Patents
Tel: 9215488